Takeda Pharmaceutical Company Limited (NYSE:TAK) · earnings preview
Quarter
Q2
EPS estimate to actual
$0.31
Revenue estimate to actual
$7.2B
At a glance
Key takeaways
01Takeda Pharmaceutical will report Q2 2026 earnings on October 29, 2026 after market close with expected EPS of $0.31 versus $0.00 in the prior year quarter.
02Revenue is projected at $7.2 billion, representing growth from the year-ago quarter, with the stock currently trading at $20.14 and a market cap of $45.4 billion.
03Recent earnings history shows mixed performance, with Q1 beating estimates by 23.8% and Q4 by 35.2%, but Q3 missing by 13.6%.
04Investors should evaluate revenue growth, margin trends, and forward guidance alongside headline EPS when assessing the stock's direction after earnings.
Analysts expect the Healthcare company to report earnings per share of $0.31, above the $0.00 reported in the same quarter last year. Revenue is expected to come in at $7.2B, up from a year ago.
Company Overview
The stock currently trades at $20.14 with a market capitalization of $45.4B.
Ahead of Takeda Pharmaceutical Company Limited's earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Takeda Pharmaceutical Company Limited should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Takeda Pharmaceutical Company Limited Earnings History